Gulf Coast Regional Blood Center competitors

Michael Parejko is a Chief Executive Officer - Mississippi Valley Regional Blood Center at Mississippi Valley Regional Blood Center and is based in Davenport, Iowa. He has worked as COO/ EVP Indiana Blood Center at Indiana Blood Center, Medical Technologist at Northwestern Memorial Hospital, and Director of US Sales- Eastern Region at Pall Corporation. Michael works or has worked as Board Member at United Way of the Quad Cities Area. He studied at Indiana Wesleyan University between 2005 and 2007 and NMU between 1983 and 1988.

John Armitage is a CEO at Oklahoma Blood Institute, President at Global Blood Fund, and Manager at ALLIANCE FOR COMMUNITY TRANSFUSION SERVICES LLC and is based in London, Oklahoma City, Oklahoma. He has worked as Exec Director at New Jersey Blood Services, CEO and Medical Director at Appalachian Region - Am Red Cross, and CEO at Greater Alleghenies Region - Am Red Cross. John studied at Duke University School of Medicine, Yale, and North Carolina School of Science & Mathematics.

Andrei Soran is a Chief Executive Officer at Trident USA Health Services.

Recognized strategic industry leader with twenty-five+ years and 150+ cases of advisory, transaction and interim executive experience. Opened and led the Phoenix Boston office since its inception in 2000. Experiences include a wide variety of executive and advisory roles in public, private-family & PE sponsored companies, M&A investment banking assignments, financial & operational transaction support diligence, operational wind downs and bankruptcy §363 transactions. Effective results driven by ability to build teams and establish consensus in a wide array of corporate environments illustrates unique ability to adapt to the distinctive elements of each situation. Communication style and approach is to provide leadership and insight for effective execution of strategies and goals.

With years of clinical leadership experience, Dr. Kevin Klauer brings valuable and innovative talents to the team. Dr. Klauer is a proven leader and brings his expertise and knowledge to the company as the chief medical officer for Emergency Medicine, chief risk officer for TeamHealth, and executive director of TeamHealth’s Patient Safety Organization. He works hard to develop cutting-edge patient safety and clinical best practices throughout the organization and directs clinical risk management. Dr. Klauer is responsible for: • risk management initiatives • clinical education • litigation support • patient safety • assistance with training medical directors • promotion of effective communication with physicians and advanced practice clinicians Concurrent with his role at TeamHealth, Dr. Klauer is an assistant clinical professor at Michigan State University College of Osteopathic Medicine and serves as the medical editor-in-chief for ACEP Now, the monthly publication of the American College of Emergency Physicians (ACEP). He previously served as editor-in-chief for Emergency Physicians Monthly. Dr. Klauer has published three risk-management books, Emergency Medicine Bouncebacks: Medical and Legal, Risk Management and the Emergency Department: Executive Leadership and Protecting Patients and Hospitals, with a third, Pediatric Bouncebacks, released in March 2015. Dr. Klauer also served as a speaker of the ACEP Council. Dr. Klauer received the ACEP National Teaching Faculty Award in 2001 and the Emergency Medicine Resident's Association Robert Dougherty ACEP/Emergency Medicine Foundation Teaching Fellowship. In 2014, he was the recipient of ACEP's Honorable Mention Outstanding Speaker of the Year Award and was recognized by the Ohio Chapter of ACEP with the Bill Hall Award of Service. Dr. Klauer earned his Executive Juris Doctor with honors from Concord Law School in 2011.

Lloyd Sanders joined Epic Sciences as President and Chief Executive Officer in 2019 with more than 20 years of diagnostics and pharmaceutical industry experience, most of it focused on oncology. Prior to joining Epic, he served as president of the oncology segment of Myriad Genetics, overseeing the oncology, urology and dermatology commercial organizations. While at Myriad, he was responsible for the sales, marketing, medical, customer service and laboratory operations for numerous market-leading commercial products, including molecular diagnostics for risk assessment, diagnosis/screening, prognosis and selection of therapies for breast, prostate, colorectal and other cancers. Previously, Mr. Sanders served as chief operating officer at Dey Pharma, a division of Mylan, overseeing sales, marketing and medical affairs, including the EpiPen® flagship brand. Prior to Dey Pharma, he held several leadership positions including responsibility for the commercial growth of a number of oncology products at Sanofi-Synthelabo, subsequently Sanofi-Aventis, where he led the successful restructuring and integration of two companies’ sales forces after the merger. Mr. Sanders started his pharmaceutical career and participated in oncology product launches at Pharmacia (now Pfizer). Mr. Sanders earned a Bachelor’s business degree with an emphasis in marketing from Memphis State University.